Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28223062

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2017 Apr
First author
Morris VK

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Apr;18(4):415-416. doi: 10.1016/S1470-2045(17)30091-8.
    note
    Source null
    related pmid
    28223061
    relationship
    Comment in
  2. citation
    Strahlenther Onkol. 2018 Apr;194(4):356-357. doi: 10.1007/s00066-018-1272-8.
    note
    Source null
    related pmid
    29392353
    relationship
    Comment in

Authors and identifiers

  1. name
    Morris VK
    type
    Author
  2. name
    Salem ME
    type
    Author
  3. name
    Nimeiri H
    type
    Author
  4. name
    Iqbal S
    type
    Author
  5. name
    Singh P
    type
    Author
  6. name
    Ciombor K
    type
    Author
  7. name
    Polite B
    type
    Author
  8. name
    Deming D
    type
    Author
  9. name
    Chan E
    type
    Author
  10. name
    Wade JL
    type
    Author
  11. name
    Xiao L
    type
    Author
  12. name
    Bekaii-Saab T
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Morris VK
    type
    Author
  2. name
    Salem ME
    type
    Author
  3. name
    Nimeiri H
    type
    Author
  4. name
    Iqbal S
    type
    Author
  5. name
    Singh P
    type
    Author
  6. name
    Ciombor K
    type
    Author
  7. name
    Polite B
    type
    Author
  8. name
    Deming D
    type
    Author
  9. name
    Chan E
    type
    Author
  10. name
    Wade JL
    type
    Author
  11. name
    Xiao L
    type
    Author
  12. name
    Bekaii-Saab T
    type
    Author
bibliography ids
  1. nci-bib-d5728b7eab9149cb74ec4708
book metadata
content sha256
83af4b7d6f389f87c12aa318a7b397d330e1d274acf08acacda6355884c15d01
document type
citation
dois
  1. 10.1016/S1470-2045(17)30104-3
electronic publication date
display
2017 Feb 18
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:28223062
immutable id
pubmed:28223062@83af4b7d6f389f87c12aa318a7b397d330e1d274acf08acacda6355884c15d01
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
4
name
The Lancet. Oncology
nlm unique id
100957246
pages
446-453
volume
18
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2017 Apr;18(4):415-416. doi: 10.1016/S1470-2045(17)30091-8.
    note
    Source null
    related pmid
    28223061
    relationship
    Comment in
  2. citation
    Strahlenther Onkol. 2018 Apr;194(4):356-357. doi: 10.1007/s00066-018-1272-8.
    note
    Source null
    related pmid
    29392353
    relationship
    Comment in
outcomes validated
false
pmid
28223062
provenance
batch id
7a1288ac8bb5f9826304
provider
NCBI PubMed ESummary
record sha256
b720f9ec01228953369fbff84b34bdd712f6a10c8f44ddc2d0a5871c7febd6c8
response sha256
0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
retrieved at
2026-09-09T23:47:23.138359+00:00
publication date
display
2017 Apr
precision
month
year
2017
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/28223062/
title
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.

Preserved source evidence · Not medical advice